[Pegfilgrastim in hematopoietic stem cell transplantation]

Area of Science:

• Pharmacology
• Hematology
• Oncology

Background:

• Filgrastim, a granulocyte colony-stimulating factor (G-CSF), is crucial for managing neutropenia after chemotherapy.
• Daily G-CSF administration presents challenges in patient compliance and healthcare resource utilization.
• Pegylation, the addition of polyethylene glycol (PEG), modifies drug properties, including extending half-life.

Purpose of the Study:

• To evaluate the efficacy and utility of pegfilgrastim as an alternative to daily G-CSF.
• To assess pegfilgrastim's role in stem cell mobilization for transplantation.
• To compare the outcomes of pegfilgrastim with G-CSF in various clinical settings.

Main Methods:

• Review of studies investigating pegfilgrastim in neutropenia recovery post-chemotherapy.
• Analysis of clinical trials assessing pegfilgrastim for hematopoietic stem cell mobilization in allogeneic and autologous transplantation.
• Comparison of pegfilgrastim's efficacy, safety, and stem cell properties against daily G-CSF.

Main Results:

• A single dose of pegfilgrastim is therapeutically equivalent to daily G-CSF for neutropenia recovery.
• Pegfilgrastim effectively mobilizes hematopoietic stem cells (CD34+) in both allogeneic donors and autologous transplant recipients.
• Outcomes suggest similar efficacy to G-CSF, with potential differences in mobilized stem cell properties requiring further investigation.

Conclusions:

• Pegfilgrastim represents a significant advancement in filgrastim therapy, offering a simplified dosing regimen.
• Its efficacy in neutropenia management and stem cell mobilization supports its use as a viable alternative to daily G-CSF.
• Further research into the functional aspects of stem cells mobilized by pegfilgrastim is warranted.